World Leading Innovators In
World Leading Innovators In
Using highly effective and responsive technology, our digital wearable devices are clinically tested, FDA cleared and endorsed by the medical profession. Easy-to-use, comfortable and adjustable, they bring a new dimension to treatment by putting people back in control.
For access to our Partners portal please enter your registration details below.
Chairman of the Board
Wilbur is the Executive Chairman of Naurex, Inc., a biopharmaceutical company, and the President of PathoCapital LLC, a private investment firm. Mr. Gantz was formerly Chairman and Chief Executive Officer of Ovation Pharmaceuticals, Inc., a position assumed in 2002. Previously he served as Chairman and Chief Executive Officer of PathoGenesis Corporation and as President of Baxter International Inc. Mr. Gantz serves as a director of Adams Street Partners and is a trustee of the Field Museum.
Director and CEO
Nicholas is an experienced CEO, successful executive and entrepreneur with a track record of company startups, development and exits in the OTC and Rx Pharmaceutical markets. Topaz Pharmaceuticals Inc., the company that he founded in 2005, was acquired by Sanofi Pasteur in 2011. He personally led Topaz through multiple rounds of financing, R&D (pre-clinical to FDA submission) as CEO & President and Board Member. The FDA approved Sklice®, the product that he founded the company upon, on Feb 7, 2012 – a major achievement for a small startup company. Nick has worked closely with digital healthcare companies as well as middle to big Pharma companies advising them at the highest level on business strategies and life cycle management. Prior to that he enjoyed a global career at Merck as a senior manager in many countries worldwide. Nick is also a Business Adviser with the Science Center of Philadelphia’s QED program for innovation, an Adjunct Professor of Pharmaceutical and Healthcare business at the University of Sciences, Philadelphia and was recently elected to the Commercialization Advisory Board of Penn State College of Medicine.
David is the Founder, President and Chief Executive Officer of JVC Investment Partners LLC, since October 2000, a firm that provides private investment and strategic support to early stage and middle market businesses in the healthcare space. Mr. Jonas founded PHC in 2003 and was its Chairman and Chief Executive Officer until January 2014 and continue to be a member of its board of directors. Prior to founding JVC Investment Partners and PharMEDium, Mr. Jonas held a number of senior management position with Baxter including the co-founder and COO/CFO of Renal Therapy Services Worldwide Inc. a subsidiary of Baxter International Inc. Mr. Jonas served on boards of various privately held companies and non-for-profit organizations including the Chicago Medical School, Gore-Bronson Bancorp, Healthcare Venture Fund, Medica Venture Fund, IBAX Healthcare Systems. Mr Jonas received BS degree in Finance and MBA from Roosevelt University. Mr. Jonas business management experience, spanning more than 35 years, includes extensive strategic and operational experience in product development, manufacturing, sales and distribution of critical healthcare products and services.
Cameron is an accomplished pharmaceuticals and biotech entrepreneur, marketer, financing, business and corporate development professional with a strong medical base. He has served as chairman and director on the boards of numerous companies, and operated as CEO or interim CEO for four venture-backed companies. In other assignments, he has been a senior executive at Johnson and Johnson, Pharmacia Corporation, GSK and Merck,. He has served as the founding investor, Chairman and CEO of publicly-traded PediaRX (acquired by Apricus Biosciences, a NASDAQ company), Executive Chairman of publicly traded Anavez, CEO of PediaMed Pharmaceuticals (acquired by Connetics Corporation and also Tiber Labs), Chairman of Pressure Point (now with an FDA-cleared, marketed medical device), founding director of Bexion Pharmaceuticals (now with a Phase I, novel lipid/protein nanotech oncology therapeutic/imaging agent), board member of Topaz Pharmaceuticals (acquired by Sanofi-Pasteur), board member of PDS Biotechnology Corporation and founder investor in Prism Pharmaceuticals (acquired by Baxter). He has been involved in 5 exits, ranging from a 2-9x return. Dr. Durrant has been an advisor to Microsoft Corporation, Aprecia Pharmaceuticals, Pilgrim Software (acquired by a private equity group), PathXL and Saxa Private Equity Partners. He has also been involved in creating companies around targeted early-stage technologies with Cincinnati Children’s Hospital and assisted numerous private equity groups in their diligence efforts, leading to successful deal closure. He has raised significant capital in VC, private equity, angel and high net worth financings.
General Counsel and Secretary
Jeffrey is a partner of the law firm of Fox Rothschild LLP and Chair of the Firm’s Corporate Department, focuses his practice on capital formation, public company reporting, compliance and transactions, corporate governance, and M&A. This includes working with Boards of Directors and entrepreneurs at each point in the life cycle of business formation, growth and exit transactions. Jeff serves many clients as general counsel where he combines his broad legal experience with a practical business sense. Jeff is a member of Fox Rothschild’s Executive Committee and is managing partner of the firm’s 30 lawyer Bucks County office. Jeff serves as managing director of Delaware Crossing Investor Group (www.delawarecrossing.org), an angel investor network conceived of and managed with two Fox Rothschild colleagues. Jeff is a member of the Executive Committee of Heritage Conservancy, a leading regional land preservation group. He is also active in Fisherman’s Mark, a not-for-profit which provides assistance to the needy in the Lawrenceville, NJ area. Jeff has served in a number of other leadership roles at Fox Rothschild, including Chair of the Emerging Companies Practice Group and Chair of Public Companies Practice Group.